Kineta, Inc. (KANT) - Total Liabilities
Based on the latest financial reports, Kineta, Inc. (KANT) has total liabilities worth $9.38 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kineta, Inc. - Total Liabilities Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Kineta, Inc. (KANT) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Kineta, Inc. Competitors by Total Liabilities
The table below lists competitors of Kineta, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Crown Confectionery Co Ltd Pref
KO:26490K
|
Korea | ₩127.45 Billion |
|
C&C Group plc
LSE:CCR
|
UK | GBX812.48 Million |
|
Azincourt Uranium Inc
V:AAZ
|
Canada | CA$341.08K |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
Germany | €573.51K |
|
Inotiv Inc
NASDAQ:NOTV
|
USA | $625.31 Million |
|
Aro Granite Industries Limited
NSE:AROGRANITE
|
India | Rs2.20 Billion |
|
TRU PRECIOUS METALS CORP.
F:706
|
Germany | €301.38K |
|
Trinitan Metals and Minerals
JK:PURE
|
Indonesia | Rp867.76 Billion |
Liability Composition Analysis (2020–2023)
This chart breaks down Kineta, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KANT stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kineta, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kineta, Inc. (2020–2023)
The table below shows the annual total liabilities of Kineta, Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $7.22 Million | -43.86% |
| 2022-12-31 | $12.87 Million | -49.15% |
| 2021-12-31 | $25.30 Million | -29.42% |
| 2020-12-31 | $35.85 Million | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more